Warfarin treatment quality and outcomes in patients with non-valvular atrial fibrillation and CKD G3-G5D

Warfarin treatment quality and outcomes in patients with non-valvular atrial fibrillation and CKD G3-G5D

Warfarin treatment quality is calculated as time in therapeutic range (TTR). TTR ≥ 70 % is considered reducing the risk of adverse events for patients with atrial fibrillation (AF). The association of TTR and adverse events in chronic kidney disease (CKD) is however poorly investigated. The aim is t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thrombosis research 2023-09, Vol.229, p.131-138
Hauptverfasser: Welander, Frida, Renlund, Henrik, Dimény, Emöke, Holmberg, Henrik, Själander, Anders
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulation
Atrial fibrillation
Bleeding
Chronic kidney disease
Dialysis
Ischemic stroke
Warfarin
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Warfarin treatment quality is calculated as time in therapeutic range (TTR). TTR ≥ 70 % is considered reducing the risk of adverse events for patients with atrial fibrillation (AF). The association of TTR and adverse events in chronic kidney disease (CKD) is however poorly investigated. The aim is to explore this further. Swedish cohort study based on national healthcare registers between 2009 and 2018, including Swedish Renal Registry, Swedish Stroke Register and AuriculA - the Swedish national quality register for AF and anticoagulation. Investigating the effect of individual TTR (iTTR) and iTTR ≥ 70 % versus
ISSN:0049-3848
1879-2472
1879-2472
DOI:10.1016/j.thromres.2023.07.003